Thinking of joining a study?

Register your interest

Become a volunteer?

Clinical trials

3336 results

Sort By:

Sacubitril-valsartan in Patients With Heart Failure With Reduced Ejection Fraction From Rural Tanzania

Study ID: NCT06704633
Start Date: 2026-01-05
End Date: 2028-04-30
Study Type

Interventional

Study Phase

Phase4

No. of Participants

238

Intervention / Treatment

Sacubitril / Valsartan Oral Tablet

Sponsor

Martin rohacek

Source: clinicaltrials.gov

Share:
Add to list

No Time to Pause: Physical Activity to Improve Health of Midlife Hispanic Women

Study ID: NCT06376812
Start Date: 2026-05
End Date: 2029-01
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

40

Intervention / Treatment

Physical activity intervention

Sponsor

The University of Texas Medical Branch, Galveston

Source: clinicaltrials.gov

Share:
Add to list

Preliminary Evaluation of the Safety and Tolerability of SPOT-mRNA01 Subcutaneously Administered in Healthy Subjects

Study ID: NCT06567119
Start Date: 2025-11-12
End Date: 2027-12-15
Study Type

Interventional

Study Phase

Phase1

No. of Participants

10

Intervention / Treatment

SPOT-mRNA01

Placebo

Sponsor

SIPO Biotechnology Co. Ltd.

Source: clinicaltrials.gov

Share:
Add to list

ECA-enhanced Document Explanation RCT

Study ID: NCT06435819
Start Date: 2026-09-01
End Date: 2027-09-01
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

300

Intervention / Treatment

Embodied Conversational Agent (ECA)

Sponsor

Northeastern University

Source: clinicaltrials.gov

Share:
Add to list

A Study of Donanemab, RG6289, or the Combination of Donanemab and RG6289 in Presenilin 1 (PSEN1) E280A Mutation Carriers for the Treatment of Autosomal-Dominant Alzheimer's Disease

Study ID: NCT06996730
Start Date: 2026-01-15
End Date: 2030-06-01
Study Type

Interventional

Study Phase

Phase3

No. of Participants

240

Intervention / Treatment

Donnemab

RG6289

Donnemab placebo

RG6289 placebo

Sponsor

Banner Health

Source: clinicaltrials.gov

Share:
Add to list

Benefits of Exergames on Neurocognitive Functions in Adults Suffering From Depression

Study ID: NCT06536530
Start Date: 2027-01
End Date: 2029-03
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

150

Intervention / Treatment

Exergame-Based Training

Cognitive-Based Training

Wait-List

Sponsor

MAP Institute

Source: clinicaltrials.gov

Share:
Add to list

A Study to Evaluate Immunogenicity and Safety After the First and Second Doses of MG1111 (BARYCELA Inj.) in Healthy Children Aged 12 Months to 12 Years

Study ID: NCT07054099
Start Date: 2026-03
End Date: 2036-07
Study Type

Interventional

Study Phase

Phase3

No. of Participants

474

Intervention / Treatment

MG1111 (Barycela inj.)

VARIVAX™

Sponsor

GC Biopharma Corp

Source: clinicaltrials.gov

Share:
Add to list

Effect of Progesterone Administration on Severely Head Injured Patients

Study ID: NCT06631547
Start Date: 2025-12-01
End Date: 2027-07-01
Study Type

Interventional

Study Phase

Phase1

No. of Participants

50

Intervention / Treatment

Progesterone

The usual head trauma care

Sponsor

Assiut University

Source: clinicaltrials.gov

Share:
Add to list

Toward Ubiquitous Lower Limb Exoskeleton Use in Children and Young Adults

Study ID: NCT06998134
Start Date: 2025-09-10
End Date: 2028-08-18
Study Type

Observational

Study Phase

Not Applicable

No. of Participants

23

Intervention / Treatment

Extension assist knee ankle foot orthosis (EA-KAFO)

Sponsor

National Institutes of Health Clinical Center (CC)

Source: clinicaltrials.gov

Share:
Add to list

Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)

Study ID: NCT07104032
Start Date: 2025-11
End Date: 2029-12
Study Type

Interventional

Study Phase

Phase3

No. of Participants

132

Intervention / Treatment

Gibberish

Rituximab

Temozolomide

Sponsor

Ono Pharmaceutical Co. Ltd

Source: clinicaltrials.gov

Share:
Add to list